References:
1. Poddubnyy D, Rudwaleit M. Early spondyloarthritis. Rheum Dis Clin North Am. mai 2012;38(2):387‑403.
2. Samia B, Hazgui F, Abdelghani KB, Hamida FB, Goucha R, Hedri H, et al. Atteinte rénale au cours de la spondylarthrite ankylosante. Néphrologie Thérapeutique. 1 juill 2012;8(4):220‑5.
3. Lee S-H, Lee EJ, Chung SW, Song R, Moon J-Y, Lee S-H, et al. Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int. juill 2013;33(7):1689‑92.
4. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. juin 2009;68(6):770‑6.
5. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524‑30.
6. Ben Taarit C, Ajlani H, Ben Moussa F, Ben Abdallah T, Ben Maïz H, Khedher A. Les manifestations rénales de la spondylarthrite ankylosante : à propos de 210 cas. Rev Médecine Interne. 1 déc 2005;26(12):966‑9.
7. Cadiñanos J, Costa R, Trujillo D, Real de Asúa D. [Systemic secondary AA amyloidosis]. Med Clin (Barc). 1 avr 2015;144(7):324‑30.
8. Shu KH, Lian JD, Yang YF, Lu Y, Wang JY, Lan JL, Chou G. Glomerulonephritis in ankylosing spondylitis. Clin Nephrol 1986;25: 169–71.
9. Swaak AJG, Frankfort I, Menon RS, Planten O, Pekelharing JM. Absence of IgA nephropathy in patients with ankylosing spondylitis. Rheumatol Int 1986;6:145–9.
10. Steisson K, Hirszel P, Weinstein A. Mesangial IgM nephropathy in a patient with HLA-B27 spondylarthropathy. Arthritis Rheum 1983;26: 1056.
11. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524‑30.
12. Frikha F, Kaddour N, Frigui M, Jallouli M, Marzouk S, Meftah S, et al. L’atteinte rénale au cours de la spondylarthrite ankylosante. Rev Rhum. 1 nov 2006;73(10):1251.
13. Jones DW, Mansell MA, Samuell CT, Isenberg DA. Renal abnormalities in ankylosing spondylitis. Br J Rheumatol. oct 1987;26(5):341‑5.
14. Paueksakon P, Fogo AB. Drug-induced nephropathies. Histopathology. 2017;70(1):94-108.
15. Artinano M, Etheridge WB, Stroehlein KB, Barcenas CG. Progression of minimal-change glomerulopathy to focal glomerulosclerosis in a patient with fenoprofen nephropathy. Am J Nephrol. 1986;6(5):353-7.
16. Andrews PA, Sampson SA. Topical non-steroidal drugs are systemically absorbed and may cause renal disease. Nephrol Dial Transplant. 1999;14(1):187-9.
17. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol. 2015;10(7):1291-9.
18. Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, et al. Adalimumab in the Treatment of Immune-Mediated Diseases. Int J Immunopathol Pharmacol. janv 2014;27(1_suppl):33‑48.
19. Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol. 22 juill 2015;16:111.
20. Liu Y, Shi Y, Ren R, Xie J, Wang W, Chen N. Advanced therapeutics in focal and segmental glomerulosclerosis: Advanced therapeutics in FSGS. Nephrology. oct 2018;23:57‑61.